ClinicalTrials.gg
Enrolling by invitationNCT06723015Updated Oct 30, 2026

Tau PET Outcomes With Anti-amyloid Immunotherapies

A Phase 2 interventional study of 18F-AV-1451 and C-11 ER-176 in Cognitive Impairment, Mild, Dementia, Mild and Alzheimer Disease, sponsored by Mayo Clinic. Enrolling by invitation at 1 site in United States. Open to participants aged 50 Years to 90 Years. Per ClinicalTrials.gov, last updated 2026-10-30.

Sponsored by Mayo Clinic · Phase 2, Interventional, and Other

How we know

Updated Oct 30, 2026Interventions changedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
135
Allocation
Non-randomized
Ages
50 Years to 90 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 22 studies in Cognitive Dysfunction by Mayo Clinic — 7 open to participants now, 9 under way, none of them phase 3. Cognitive Dysfunction · Mayo Clinic.

Planned enrollment
4th of 17
135 · median 42
Started
2025
with 1 other
Phase 2
5 of 22
2 open now
Registered
20th of 22
by date

Among the 22 studies in Cognitive Dysfunction by Mayo Clinic, this one is the 4th largest by planned enrollment of the 17 interventional ones that give a count, is one of 2 that started in 2025, is one of 5 in phase 2, and was the 20th registered.

Cognitive Dysfunction

3,885 studies on the registry are indexed under Cognitive Dysfunction; 1,123 are open to participants now.

Browse Cognitive Dysfunction studies →

Open to participants now

7 of the 22 studies in Cognitive Dysfunction by Mayo Clinic are open now, in 1 country. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 7 open studies →

Where they have run

Who these studies take

Of the 751 Cognitive Dysfunction studies recruiting now, 361 (48%) set no upper age limit and 144 (19%) stop at 75 or younger; 46 take children under 18; 260 take healthy volunteers.

This study: 50 Years to 90 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies in Cognitive Dysfunction by Mayo Clinic, or all of them as a file.
02

Study summary

This is an imaging study of patients with mild Alzheimer's disease receiving amyloid-targeting therapy and under the care of neurologists at Mayo Clinic in Rochester, MN.

03

Conditions studied

  • Cognitive Impairment, Mild
  • Dementia, Mild
  • Alzheimer Disease
04

Who can participate

Ages eligible
50 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 50-90 years
  • Male or female
  • Mild cognitive impairment due to AD or mild AD
  • Amyloid positive via CSF or PET
  • Meets other eligibility criteria for anti-amyloid immunotherapy
  • Subject or delegate provides

Exclusion criteria

Exclusion Criteria

  • Subjects unable to lie down without moving for 10 minutes.
  • Women who are pregnant or cannot stop breast feeding for 24 hours.
  • Claustrophobic patients unable to tolerate the scans (no sedation can be offered).
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 2
Primary purpose
Other
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
135 participants (estimated)

Study arms

  • No intervention
    Control Group

    Untreated historical controls enrolled in Mayo Clinic Study of Aging (IRB 14-004401), Mayo Alzheimer's Disease Research Center (IRB 712-98), and Brain Amyloid Imaging with Pittsburgh Compound B in Normal Aging, Mild Cognitive Impairment, and Dementia (IRB 08-005553).

  • Experimental
    Treatment Group

    Subjects with a diagnosis of mild cognitive impairment (MCI) or mild dementia due to Alzheimer's disease and amyloid positive, who are starting anti-amyloid immunotherapy.

    Drug: 18F-AV-1451 · Drug: C-11 ER-176

Interventions

  • Drug18F-AV-1451

    Subjects will receive two Tau PET (18F--AV-1451) brain scans with approximately 10 mCi (370 MBq) (+/- 10%mCi) of 18F-AV-1451. Images will be collected for a 20-minute acquisition between 80-100 minutes after injection. Tau PET scans will occur at baseline and 12-18 months after completing anti-amyloid immunotherapy treatment..

  • DrugC-11 ER-176

    For the optional TSPO PET scans, C-11 ER176 will be administered as a single time IV injection prior to PET imaging. The injected dose of C-11 ER176 will be 518 MBq (14 mCi) (range 370-666 MBq; 10-18 mCi).

06

What researchers measure

Primary outcomes

  1. Change in tau PET Standardized Uptake Value (SUVR)

    A PET Standardized Uptake Value (SUV) is measured by calculating the ratio of the radioactivity concentration within a specific region of interest (ROI) on a PET scan, divided by the injected dose of the radiotracer per unit of the patient's body weight. The calculated Standardized Uptake Value (SUVR) is reported as a single number, with higher values indicating greater tracer uptake in the target region relative to the reference region

    Time frame: Baseline, 18 months

Secondary outcomes

  1. Number of subjects to develop amyloid-related imaging abnormalities (ARIA)

    ARIA is defined as edema (parenchymal edema or sulcal effusion, ARIA-E) and hemorrhage (microhemorrhages and superficial siderosis, ARIA-H). ARIA is detected on the patient's routine clinical brain MRIs.

    Time frame: 18 months

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2025 (actual). Primary completion is estimated for Aug 2028, 33 months after the start.

Of 145 non-industry phase 2 interventional studies under Cognitive Dysfunction, half reached primary completion within 53 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 64. This study's planned 33 months is below that.

Counting every sponsor, half of 187 studies reached it within 42 months; a quarter within 22 and three quarters within 62.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 5, 2024
First posted
Dec 9, 2024
StartActual
Nov 4, 2025
Primary completionEst.
Aug 2028
CompletionEst.
Aug 2028
Last update
Oct 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Interventions
Added Drug: C-11 ER-176
Oct 30, 2026
Show all 1 update
  1. Oct 30, 2026
    Interventions Added Drug: C-11 ER-176

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06723015
Lead sponsor
Mayo Clinic
Responsible party
Petrice M. Cogswell (Principal Investigator, Mayo Clinic) — Principal investigator
First posted
Dec 9, 2024
Start date
Nov 4, 2025
Primary completion
Aug 2028 (estimated)
Completion
Aug 2028 (estimated)
Last update
Oct 30, 2026

Study contacts

Petrice Cogswell, M.D., Ph.D.
principal investigator · Mayo Clinic

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion